



PATENT
ATTORNEY DOCKET: 64517.000002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Masaaki IKEDA et al.) Group Art Unit: To Be Assigned
Application Number: 10/713008) Examiner: To Be Assigned
Filed: November 17, 2003)
For: METHODS FOR PROLIFERATING TERMINAL DIFFERENTIATED CELLS
AND RECOMBINANT VECTORS THEREFOR

INFORMATION DISCLOSURE STATEMENT

Mail Stop Patent Application

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In accordance with 37 C.F.R. §§ 1.56, 1.97, and 1.98, Applicant respectfully requests consideration of the references listed on the attached Form PTO/SB/08A. Copies of the references listed are also enclosed.

Applicant respectfully requests that the Examiner consider the references cited on the Form PTO/SB/08A and that the Examiner indicate that the references have been considered in this application by returning a copy of the Form PTO/SB/08A with the Examiner's initials in the left column per MPEP 609.


Applicants' submission of this Information Disclosure Statement (IDS) shall not be construed as an admission that the cited references are prior art to the present invention, or that the cited references qualify as printed publications. The submission of this IDS also shall not be construed as a representation that a prior art search has been performed.

This IDS is submitted prior to the issuance of a first Office Action on the merits; therefore, it is believed that no fees are required in connection therewith. If any fees are necessitated by the filing of this Information Disclosure Statement, please charge the undersigned's Deposit Account No. 50-0206.

Respectfully submitted,

Date: 1 Dec 2003

By:


Robert M. Schulman
Registration No. 31,196

Jeffrey T. Perez
Registration No. 52,110

HUNTON & WILLIAMS LLP
1900 K Street, N.W., Suite 1200
Washington, DC 20006-1109
(202) 955-1500 (telephone)
(202) 778-2201 (facsimile)

RMS/JTP/cbt

DEC 01 2003

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number	To Be Assigned
Filing Date	November 17, 2003
First Named Inventor	Masaaki IKEDA
Group Art Unit	To Be Assigned
Examiner Name	To Be Assigned

Attorney Docket Number

64517.000002

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	U1					
	U2					
	U3					
	U4					
	U5					

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	P1	DAVEY, J. et al., "Identification of the Sequence Responsible for the Nuclear Accumulation of the Influenza Virus Nucleoprotein", <i>Cell</i> (1985), Vol. 40, pp. 667-675.	
	P2	KALDERON, D. et al., "Sequence requirements for nuclear location of simian virus 40 large-T antigen", <i>Nature</i> (1984), Vol. 311, pp. 33-38.	
	P3	KIRSHENBAUM, L. A. et al., "Adenovirus E1A Represses Cardiac Gene Transcription and Reactivates DNA Synthesis in Ventricular Myocytes, via Alternative Pocket Protein- and p300-binding Domains", <i>The Journal of Biological Chemistry</i> (1995), Vol. 270, pp. 7791-7794.	
	P4	KIRSHENBAUM, L.A. et al., "Human E2F-1 Reactivates Cell Cycle Progression in Ventricular Myocytes and Represses Cardiac Gene Transcription", <i>Developmental Biology</i> (1996), Vol. 179, pp. 402-411.	

Examiner Signature


Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	To Be Assigned
Filing Date	November 17, 2003
First Named Inventor	Masaaki IKEDA
Group Art Unit	To Be Assigned
Examiner Name	To Be Assigned
Attorney Docket Number	64517.000002

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	P5	LEONE, G. et al., "Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F, <i>Nature</i> (1997), Vol. 387, pp. 422-426.	
	P6	LEW, D. et al., "Isolation of Three Novel Human Cyclins by Rescue of G1 Cyclin (Cin) Function in Yeast", <i>Cell</i> (1991), Vol. 66, pp. 1197-1206.	
	P7	MATSUNSHIME, H. et al., "Colony-Stimulating Factor 1 Regulates Novel Cyclins during the G1 Phase of the Cell Cycle", <i>Cell</i> (1991), Vol. 65, pp. 701-713.	
	P8	MIZUGUCHI, H. et al., "Efficient Construction of a Recombinant Adenovirus Vector by an Improved <i>In Vitro</i> Ligation Method", <i>Human Gene Therapy</i> (1998), Vol. 9, pp. 2577-2583.	
	P9	ROBBINS, J. et al., "Two Interdependent Basic Domains in Nucleoplasmin Nuclear Targeting Sequence: Identification of a Class of Bipartite Nuclear Targeting Sequence", <i>Cell</i> (1991), Vol. 64, pp. 615-623.	
	P10	SCHOLZEN, T. et al., "The Ki-67 Protein: From the Known and the Unknown", <i>Journal of Cell Physiology</i> (2000), Vol. 182, pp. 311-322.	
	P11	SOONPAA, M. H. et al., "Cyclin D1 Overexpression Promotes Cardiomyocyte DNA Synthesis and Multinucleation in Transgenic Mice", <i>J. Clin. Invest.</i> (1997), Vol. 99, pp. 2644-2654.	
	P12	TAMAMORI, M. et al., "Essential roles for G ₁ cyclin-dependent kinase activity in development of cardiomyocyte hypertrophy", <i>the American Physiological Society</i> (1998), pp. H2036-2040.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, VA 22313-1450